Skip to main content
OpenTrials
Completed

NCT Number: NCT04841265

The Effect of Vitamin D Supplementation in Overweight and Obese Pregnant Women

To understand the role of vitamin D supplementation on pregnancy outcomes and metabolic status in overweight and obese pregnant women.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

KK Women's and Children's Hospital

Singapore

About this study

The effects of vitamin D supplementation on pregnancy outcomes and metabolic status of overweight and obese pregnant women remain uncertain. In particular, the dosage of vitamin D supplementation has not been defined in this high risk group of women. This study aims to examine whether oral supplement of vitamin D3 (cholecalciferol) in total dosage of 800 IU(prenatal multivitamin containing 400 IU vitamin D3 + 400 IU vitamin D3 alone) given to overweight and obese pregnant women since early pregnancy until delivery can improve maternal and neonatal outcomes, compared with those given prenatal multivitamin containing 400 IU vitamin D3 supplementation, a commonly given antenatal supplement in Singapore. The investigators' hypothesis is that higher dose vitamin D supplementation would lead to better outcomes in overweight and obese pregnant women. The investigators will conduct a two-arm, parallel non-blinded randomized controlled trial. Women with body mass index ≥25kg/m2 will be randomly assigned into groups with a 1:1 randomization ratio, receiving either 800 or 400 IU vitamin D3 supplementation. The study will be conducted at the antenatal clinics, KK Women's and Children's Hospital, Singapore. Measurements of serum 25-hydroxyvitamin D (25OHD), lipid profile and lifestyles information will be taken for all women at baseline (≤16 weeks gestation) and after three months of intervention (26-30 weeks gestation). All women will continue with the vitamin D3 supplementation until delivery. Primary outcomes include levels of maternal serum 25OHDconcentration and lipid profile at 26-30 gestation weeks as compared with the controls, adjusting for baseline measurements. Secondary outcomes include preeclampsia, gestational hypertension, gestational diabetes, glycaemic levels, caesarean section, gestational weight gain, preterm birth, low birth weight and small-for-gestational-age. This study will fill up the gap of knowledge regarding the role of vitamin D supplementation on pregnancy outcomes and metabolic status in overweight and obese pregnant women.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Gestation ≤16weeks (16 weeks + 6 days) upon intervention
  • Pre-pregnancy BMI ≥25 kg/m2
  • Aged 21-45 years
  • Willing and able to provide written, informed consent

Exclusion criteria

  • Having current or past hypo/hyperparathyroidism, hypercalciuria, hypercalcemia or osteomalacia
  • History of renal disease (including kidney stones and etc.), liver dysfunction, tuberculosis or sarcoidosis
  • Pre-existing diabetes mellitus or chronic hypertension
  • Taking lipid-lowering medicine
  • Gestational diabetes (as confirmed by oral glucose tolerance test) or gestational hypertensive disorder
  • Multiple pregnancy

Treatment and study plan

Vitamin D3

Dietary Supplement

The intervention arm will receive 400 IU vitamin D3 from routine antenatal multivitamin supplement tablet + 400 IU vitamin D3 daily until delivery.

Primary outcomes

  1. Change in maternal serum 25OHD concentration

    Time frame: Baseline, 26-30 gestational weeks

  2. Change in maternal total cholesterol level

    Time frame: Baseline, 26-30 gestational weeks

  3. Change in maternal HDL-cholesterol level

    Time frame: Baseline, 26-30 gestational weeks

  4. Change in maternal LDL-cholesterol level

    Time frame: Baseline, 26-30 gestational weeks

  5. Change in maternal triglyceride level

    Time frame: Baseline, 26-30 gestational weeks

Secondary outcomes

  1. Incidence of preeclampsia

    Time frame: up to delivery

  2. Incidence of gestational hypertension

    Time frame: Through pregnancy until delivery

  3. Incidence of gestational diabetes

    Time frame: Through pregnancy until delivery

  4. Fasting glucose level

    Time frame: 24-28 gestational weeks

  5. 1-hour post-load glucose level

    Time frame: 24-28 gestational weeks

  6. 2-hour post-load glucose level

    Time frame: 24-28 gestational weeks

  7. Incidence of caesarean section

    Time frame: At delivery

  8. Incidence of preterm birth (<37 weeks)

    Time frame: At delivery

  9. Incidence of low birth weight (<2500g)

    Time frame: At delivery

  10. Neonatal birth weight (g)

    Time frame: At delivery

  11. Neonatal birth length (cm)

    Time frame: At delivery

  12. Neonatal head circumference (cm)

    Time frame: At delivery

  13. Incidence of admission to special care (including intensive care) during neonatal period

    Time frame: Within 28 days after delivery

Sponsors and collaborators

Lead sponsor

KK Women's and Children's Hospital

Other Gov

Registry information

Important dates

Study start
2021
Primary completion
2023
Study completion
2024
First posted
Apr 12, 2021
Registry last updated
Jul 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.